Keyphrases
Lipopolysaccharide-induced
63%
Lung
52%
Neutrophils
49%
Human Neutrophils
49%
Lipopolysaccharide
38%
C-Jun N-terminal Kinase
37%
Kidney Transplant Recipients
37%
Vaccination
32%
Dialysis Patients
31%
Pulmonary Inflammation
29%
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
23%
P38 Mitogen-activated Protein Kinase (p38 MAPK)
22%
Tumor Necrosis Factor-α
22%
LPS-induced Inflammation
22%
Klebsiella Pneumoniae (K. pneumoniae)
21%
Pneumonia
21%
Dialysis
21%
Neutrophil Recruitment
21%
Kinase Activation
20%
Antibacterial Defense
18%
IL-1R
18%
TIRAP
18%
Pseudomonas Aeruginosa (P. aeruginosa)
18%
Adaptor Protein
18%
Host Defense
18%
Cdc42
18%
Antibody Decline
18%
Medical Personnel
18%
Neutrophil Accumulation
17%
Receptor-binding Domain
16%
Vaccine Types
16%
Acute Lung Inflammation
15%
Seroconversion
14%
IgG Antibody
13%
Actin Assembly
13%
Lung Inflammation
13%
Neutrophil Influx
13%
Older Women
12%
Transplant Patients
12%
Monocyte Chemoattractant protein-1 (MCP-1)
12%
Hospitalization
11%
Cellular Immunity
11%
Hematopoietic Stem Cell Transplantation
11%
Plasminogen Activator inhibitor-1 (PAI-1)
11%
Mononuclear Cells
11%
Leukocytes
11%
Humoral Immunity
11%
Hematopoietic Stem Cell Transplant
10%
Humoral Response
10%
Renal Transplant
10%
Medicine and Dentistry
Kidney Graft
44%
Seroconversion
27%
Humoral Immunity
26%
SARS Coronavirus
23%
Messenger RNA
23%
Hematopoietic Stem Cell Transplantation
23%
Clinician
21%
Severe Acute Respiratory Syndrome Coronavirus 2
20%
Receptor Binding
18%
Cellular Immunity
18%
COVID-19
13%
Lung
12%
mRNA Vaccine
11%
Interferon
11%
Observational Study
10%
Acute Lung Injury
10%
Platelet
10%
Infectious Complication
9%
Conditioning
9%
Acute Respiratory Distress Syndrome
9%
Hypoglycemia
9%
Disseminated Intravascular Coagulation
9%
Hyperammonemia
9%
Engraftment
9%
Lactic Acidosis
9%
Löffler's Syndrome
9%
COVID-19 Vaccination
9%
Restrictive Lung Disease
9%
Mediator
9%
Chimeric Antigen Receptor T-Cell Therapy
9%
Pulmonary Hemorrhage
9%
Chimeric Antigen Receptor T-Cell
9%
Mycoplasma Pneumonia
9%
Leukocyte
9%
Mycophenolic Acid
9%
Bronchiolitis
9%
Tumor Necrosis Factor Alpha Converting Enzyme
9%
Ureaplasma
9%
Interleukin 18
9%
Graft Versus Host Reaction
9%
Endotoxemia
9%
Bleeding
9%
Mycophenolate Mofetil
9%
Hybrid Immunity
9%
Lung Lavage
8%
Diseases
7%
Release Assay
7%
Chronic Graft Versus Host Disease
7%
Immunoglobulin A
7%
Immunosuppressive Drug
6%
Immunology and Microbiology
Neutrophil
100%
Pulmonary Inflammation
43%
Tumor Necrosis Factor
34%
Mediator
29%
Amino Terminal Sequence
28%
Mitogen
23%
Klebsiella pneumoniae
18%
Pseudomonas aeruginosa
18%
Cytokine
14%
Mononuclear Cell
11%
Leukocyte
11%
Humoral Immunity
10%
Neutrophil Granulocyte
10%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Mycophenolic Acid
9%
Lipid Raft
9%
CCL2
9%
2,5-Dimethoxy-4-iodoamphetamine
9%
Interleukin 18
9%
ADAM17
9%
Mycophenolate Mofetil
9%
SARS Coronavirus
9%
Hybrid Immunity
9%
COVID-19
9%
Angiotensin
9%
Bradykinin
9%
Monocyte Chemotactic Protein 1
7%
Superoxide
6%
Actin Polymerization
6%
Interferon Type I
5%
Chemokine
5%
Knockout Mouse
5%
Macrophage Inflammatory Protein 2
5%
Complement Factor B
5%
Agonist
5%